Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer.

Rossi, Sandro; Stasi, M.; Buscarini, Elisabetta; Quaretti, Pietro; Garbagnati, F; Squassante, Lisa; Paties, Carlo; Silverman, David; Buscarini, L

doi:10.2214/ajr.167.3.8751696

Cited by 758 publications

(468 citation statements)

References 26 publications

Supporting

Mentioning

436

Contrasting

Unclassified

Order By: Relevance

“…RF-induced thermal ablation has proven to be a safe and effective modality for the treatment of small hepatic tumors in patients who are considered to be unsuitable for surgical intervention. 7,21,22 The treatment time is shorter Figure 2. Overall recurrence rates in the 2 groups are shown.…”

Section: Discussionmentioning

confidence: 99%

“…4 Various local ablation therapies such as percutaneous ethanol injection 5,6 or percutaneous radiofrequency ablation (RFA) have been proposed as nonsurgical treatment options for small-sized HCCs, and excellent survival rates have been reported with these treatments. 7,8 Complete necrosis was achieved in 76% to 100% of the treated small-sized HCCs. 8,9 However, because of the limited coagulative necrosis induced by RFA alone, in larger HCCs, the percentage of cases showing complete necrosis varied between 29% and 70%.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Midterm outcomes in patients with intermediate‐sized hepatocellular carcinoma

Morimoto

Numata

Kondou

et al. 2010

Cancer

287

View full text Add to dashboard Cite

BACKGROUND:To improve the efficacy of radiofrequency ablation (RFA) for the treatment of intermediate-sized hepatocellular carcinomas (HCCs), the authors compared RFA combined with transcatheter arterial chemoembolization (TACE) to RFA alone. METHODS: The authors randomly assigned 37 patients with solitary HCCs (diameter, 3.1-5.0 cm in the greatest dimension) to 2 groups: the TACE-RFA group, in which the patients received TACE followed by RFA on the same day, and the RFA group, in which the patients received only RFA. RESULTS: Technical success was achieved after 1.4 AE 0.5 RFA sessions in the RFA group and after 1.1 AE 0.2 RFA sessions in the TACE-RFA group (P < .01). The mean diameters of the longer and shorter axes of the RFA-induced ablated areas were 50 AE 8.0 mm and 41 AE 7.1 mm, respectively, in the RFA group and 58 AE 13.2 mm and 50 AE 11.3 mm, respectively, in the TACE-RFA group; the mean diameters of the shorter axes were significantly different (P ¼ .012). The rates of local tumor progression at the end of the third year in the RFA and TACE-RFA groups were 39% and 6%, respectively (P ¼ .012). The 3-year survival rates of the patients in the RFA and TACE-RFA groups were 80% and 93%, respectively (P ¼ .369). CONCLUSIONS: In patients with intermediate-sized HCCs, RFA combined with TACE is more effective than RFA alone for extending the ablated area in fewer treatment sessions and for decreasing the local tumor progression rate. Cancer 2010;116:5452-60.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Midterm outcomes in patients with intermediate‐sized hepatocellular carcinoma

Morimoto

Numata

Kondou

et al. 2010

Cancer

287

View full text Add to dashboard Cite

show abstract

“…Lately, there has been a growing multidisciplinary consensus regarding the promising therapeutic role of RFA for primary and secondary hepatic tumors. Early optimistic studies demonstrate favorable morbidity, mortality, recurrence and survival rates using this technique [8,9].…”

Section: Discussionmentioning

confidence: 97%

Percutaneous radiofrequency ablation of hepatocellular carcinoma in the presence of portal vein thrombosis

et al. 2003

View full text Add to dashboard Cite

Portal vein thrombosis (PVT) may not be an absolute contraindication for hepatic radiofrequency ablation (RFA). Although the data are sparse, PVT is commonly considered a contraindication to RFA. PVT has actually been described as a complication following RFA. RFA was used to treat a 3.9 × 2.9 cm primary hepatocellular carcinoma (HCC) in a patient with concomitant PVT without complication. RFA can be safely performed in this setting but further studies could clarify this issue.

show abstract

“…14 Radiofrequency interstitial tumor ablation has been used to treat primary or metastatic liver neoplasms in patients unsuitable for surgery, with encouraging results, [15][16][17][18] and has recently been proposed for use the treatment of prostate cancer. [7][8][9][10] The histopathological effects of RITA treatments have received little attention so far, however.…”

Section: Histopathological Findings After Rfmentioning

confidence: 99%

Histopathological findings after radiofrequency (RITA) treatment for prostate cancer

Patriarca

Bergamaschi

Gazzano

et al. 2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Radiofrequency interstitial tumor ablation (RITA) is a thermal ablation method that uses needles and low radiofrequency (RF) energy. The aim of our study was to evaluate the histopathology of thermal lesions induced by RF energy delivered interstitially in prostate cancer patients who subsequently underwent prostatectomy, and to determine the feasibility, effectiveness and safety of this new method in a pilot study.

show abstract

Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer.

Cited by 758 publications

References 26 publications

Midterm outcomes in patients with intermediate‐sized hepatocellular carcinoma

Midterm outcomes in patients with intermediate‐sized hepatocellular carcinoma

Percutaneous radiofrequency ablation of hepatocellular carcinoma in the presence of portal vein thrombosis

Histopathological findings after radiofrequency (RITA) treatment for prostate cancer

Contact Info

Product

Resources

About